Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Introduction The epidemiology of invasive Candida infections is evolving. Infections caused by non-albicans Candida spp. are increasing; however, the antifungal pipeline is more promising than ever and is enriched with repurposed drugs and agents that have new mechanisms of action. Despite progress, unmet needs in the treatment of invasive candidiasis remain, and there are still too few antifungals that can be administered orally or that have CNS penetration.Areas covered The authors shed light on those antifungal agents active against Candida that are in early- and late-stage clinical development. Mechanisms of action and key pharmacokinetic and pharmacodynamic properties are discussed. Insights are offered on the potential future roles of the investigational agents MAT-2203, oteseconazole, ATI-2307, VL-2397, NP-339, and the repurposed drug miltefosine.Expert opinion Ibrexafungerp and fosmanogepix have novel mechanisms of action and will provide effective options for the treatment of Candida infections (including those caused by multiresistant Candida spp). Rezafungin, an echinocandin with an extended half-life allowing for once weekly administration, will be particularly valuable for outpatient treatment and prophylaxis. Despite this, there is an urgent need to garner clinical data on investigational drugs, especially in the current rise of azole-resistant and multidrug-resistant Candida spp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Self-citationPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669 · cited 1×
“Exogenous peptides are not processed in the liver, which minimizes the risk of the involvement of NP339 in adverse drug–drug interactions [120,121].”
BackgroundDrug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642 · cited 1×
“Details regarding this concept have been provided elsewhere [21].”
BackgroundThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · cited 10×
“is comparable to those of other echinocandins [28].”
BackgroundResultInfluentialSelf-citationMuñoz, J. F., Gade, L., Chow, N. A., Loparev, V. N., Juieng, P., Berkow, E. L., Farrer, R. A., Litvintseva, A. P., & Cuomo, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07779-6 · Cited by 458 · cited 1×
“auris isolates identified multiple candidate genes potentially involved in AMB resistance [6].”
BackgroundGarcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Liu, T. T., Lee, R. E. B., Barker, K. S., Lee, R. E., Wei, L., Homayouni, R., & Rogers, P. D. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2226-2236.2005 · Cited by 313
Bowman, J. C., Hicks, P. S., Kurtz, M. B., Rosen, H., Schmatz, D. M., Liberator, P. A., & Douglas, C. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3001-3012.2002 · Cited by 303 · cited 1×
“Ibrexafungerp is fungicidal against Candida spp [28,46,47].”
Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03470-14 · Cited by 294
Cited by
Lass-Flörl, C., Kanj, S. S., Govender, N. P., Thompson, G. R., Ostrosky- Zeichner, L., & Govrins, M. A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00503-3 · Cited by 298
Self-citationDaneshnia, F., de Almeida Júnior, J. N., Ilkit, M., Lombardi, L., Perry, A. M., Gao, M., Nobile, C. J., Egger, M., Perlin, D. S., Zhai, B., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00067-8 · Cited by 257
Self-citationHoenigl, M., Salmanton-García, J., Egger, M., Gangneux, J.-P., Bicanic, T., Arikan-Akdagli, S., Alastruey-Izquierdo, A., Klimko, N., Barac, A., Özenci, V., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00872-6 · Cited by 152
Self-citationAn update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections
Jenks, J. D., White, P. L., Kidd, S. E., Goshia, T., Fraley, S. I., Hoenigl, M., & Thompson, G. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2267977 · Cited by 61
“…molds, mixed infections and infections from dimorphic fungi and also identify potential antifungal resistance through the detection of a wide range of genetic mechanisms, allowing for more targeted treatment approaches with a wide range of antifungal classes approved by then [180,181].”
BackgroundSelf-citationHoenigl, M., Egger, M., Price, J., Krause, R., Prattes, J., & White, P. L. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01859-22 · Cited by 51
“In light of a loaded antifungal pipeline with several new antifungal classes entering late-stage clinical development (27, 28), accurate detection of causative fungal species will become even more important in the near future for enabling optimal targeted treatment.”
BackgroundSelf-citation
Metadata
- Authors
- Hoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., Willinger, B., Arendrup, M. C., Koehler, P., Oliverio, M., Egger, M., Schwartz, I. S., Cornely, O. A., Pappas, P. G., & Krause, R.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2022-06-15
- Volume
- 31
- Issue
- 8
- Pages
- 795-812
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W4282020832
- Cited by
- 45
- References
- 56
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. https://app.cochat.ai/papers/10.1080/13543784.2022.2086120
- The paper
- Hoenigl, M., Sprute, R., Arastehfar, A., Perfect, J. R., Lass-Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al Obaidi, M. M., Willinger, B., Arendrup, M. C., Koehler, P., Oliverio, M., Egger, M., Schwartz, I. S., Cornely, O. A., Pappas, P. G., & Krause, R. (2022). Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2022.2086120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.